Lycera Corporation

Xiao Hu

Thomas Daniel Aicher

Peter Laurence Toogood

Gary D Glick

Clarke Bentley Taylor

Chad A Van Huis

Laura Lee Celeste

Xikui Liu

The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (ROR&#x3b3;) and provides adoptive cellular therapies using an agonist of ROR&#x3b3;, populations of lymphocyte cells that have been exposed to an agonist of ROR&#x3b3;, populations of dendritic cells that have been exposed to an agonist of ROR&#x3b3;, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of ROR&#x3b3; to a patient.

Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods

The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting RORactivity, increasing the amount of IL-17 in a subject, and treating cancer using such tetrahydro[1,8]naphthyridine and related compounds.

Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ROR&#x3b3; and the treatment of disease

The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting ROR&#x3b3; activity, increasing the amount of IL-17 in a subject, and treating cancer using such tetrahydro[1,8]naphthyridine and related compounds.

Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease

The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting ROR&#x3b3; activity, increasing the amount of IL-17 in a subject, and treating cancer, bacterial infections, and fungal infections using such tetrahydro[1,8]naphthyridine and related compounds.

Growing community of inventors

Northville, MI, United States of America

Xiao Hu